Ricardo Russo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2996946/publications.pdf

Version: 2024-02-01

80	6,482	101496	91828
papers	citations	36 h-index	69 g-index

81	81	81	5014
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	De novoCIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis and Rheumatism, 2002, 46, 3340-3348.	6.7	727
2	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2016, 68, 566-576.	2.9	427
3	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 481-489.	0.5	338
4	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. Arthritis and Rheumatology, 2014, 66, 3160-3169.	2.9	322
5	Localized scleroderma in childhood is not just a skin disease. Arthritis and Rheumatism, 2005, 52, 2873-2881.	6.7	308
6	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.5	300
7	Recommendations for the management of autoinflammatory diseases. Annals of the Rheumatic Diseases, 2015, 74, 1636-1644.	0.5	239
8	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.5	215
9	Longâ€term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. Arthritis Care and Research, 2010, 62, 63-72.	1.5	207
10	Systemic sclerosis in childhood: Clinical and immunologic features of 153 patients in an international database. Arthritis and Rheumatism, 2006, 54, 3971-3978.	6.7	189
11	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Annals of the Rheumatic Diseases, 2010, 69, 790-797.	0.5	187
12	Consensus-based recommendations for the management of juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2017, 76, 329-340.	0.5	185
13	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213030.	0.5	183
14	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis and Rheumatology, 2016, 68, 2795-2805.	2.9	168
15	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet, The, 2016, 387, 671-678.	6.3	168
16	The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis and Rheumatism, 2007, 57, 203-212.	6.7	164
17	Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. Rheumatology, 2015, 54, 1008-1016.	0.9	141
18	HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	3.3	139

#	Article	IF	Citations
19	Chronic Infantile Neurological Cutaneous and Articular/Neonatal Onset Multisystem Inflammatory Disease Syndrome<subtitle>Ocular Manifestations in a Recently Recognized Chronic Inflammatory Disease of Childhood</subtitle>. JAMA Ophthalmology, 2000, 118, 1386.	2.6	133
20	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Annals of the Rheumatic Diseases, 2017, 76, 906-913.	0.5	123
21	Ocular involvement in children with localised scleroderma: a multi-centre study. British Journal of Ophthalmology, 2007, 91, 1311-1314.	2.1	106
22	Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multiâ€national survey. Rheumatology, 2000, 39, 556-559.	0.9	99
23	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care and Research, 2010, 62, 1533-1541.	1.5	84
24	Takayasu Arteritis. Frontiers in Pediatrics, 2018, 6, 265.	0.9	84
25	Consensus-based recommendations for the management of juvenile localised scleroderma. Annals of the Rheumatic Diseases, 2019, 78, 1019-1024.	0.5	76
26	Factors affecting survival in juvenile systemic sclerosis. Rheumatology, 2009, 48, 119-122.	0.9	71
27	Clinical Remission in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Anti-Tumor Necrosis Factor Agents. Journal of Rheumatology, 2009, 36, 1078-1082.	1.0	70
28	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.5	68
29	Blau Syndromeâ€“Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series. American Journal of Ophthalmology, 2018, 187, 158-166.	1.7	62
30	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 911-923.	2.9	59
31	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open, 2016, 2, e000161.	1.8	57
32	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis. Annals of the Rheumatic Diseases, 2017, 76, 782-791.	0.5	51
33	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. Journal of Pediatrics, 2017, 189, 72-78.e3.	0.9	50
34	Validation of Relapse Risk Biomarkers for Routine Use in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2014, 66, 949-955.	1.5	47
35	IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukinâ€1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2018, 70, 1319-1330.	2.9	40
36	Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. Rheumatology, 2020, 59, 3505-3514.	0.9	39

#	Article	IF	Citations
37	Patients with Very Early-onset Systemic Juvenile Idiopathic Arthritis Exhibit More Inflammatory Features and a Worse Outcome. Journal of Rheumatology, 2013, 40, 329-334.	1.0	38
38	Clinical characteristics of children with Juvenile Systemic Sclerosis: follow-up of 23 patients in a single tertiary center. Pediatric Rheumatology, 2007, 5, 6.	0.9	37
39	A preliminary disease severity score for juvenile systemic sclerosis. Arthritis and Rheumatism, 2012, 64, 4143-4150.	6.7	36
40	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Annals of the Rheumatic Diseases, 2018, 77, 241-250.	0.5	36
41	Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. Rheumatology, 2014, 53, 665-670.	0.9	35
42	Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clinical and Experimental Rheumatology, 2011, 29, 117-24.	0.4	34
43	Etanercept in systemic juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2002, 20, 723-6.	0.4	31
44	Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind. Clinical Rheumatology, 2019, 38, 563-575.	1.0	28
45	Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. Clinical Rheumatology, 2009, 28, 985-988.	1.0	27
46	Monogenic autoinflammatory diseases. Rheumatology, 2014, 53, 1927-1939.	0.9	27
47	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.5	27
48	Basal Ganglia and Internal Capsule Stroke in Childhoodâ€"Risk Factors, Neuroimaging, and Outcome in a Series of 28 Patients: A Tertiary Hospital Experience. Journal of Child Neurology, 2009, 24, 685-691.	0.7	23
49	Biologic agents in juvenile spondyloarthropathies. Pediatric Rheumatology, 2016, 14, 17.	0.9	21
50	An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA). Pediatric Rheumatology, 2018, 16, 27.	0.9	21
51	Chronic infantile neurological cutaneous and articular syndrome: two new cases with rare manifestations. Acta Paediatrica, International Journal of Paediatrics, 2001, 90, 1076-1079.	0.7	20
52	Hepatitis A-associated macrophage activation syndrome in children with systemic juvenile idiopathic arthritis: report of 2 cases. Journal of Rheumatology, 2008, 35, 166-8.	1.0	16
53	Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. Clinical and Experimental Rheumatology, 2005, 23, 545-8.	0.4	15
54	Global damage in systemic juvenile idiopathic arthritis: preliminary early predictors. Journal of Rheumatology, 2008, 35, 1151-6.	1.0	14

#	Article	IF	Citations
55	Cross-cultural adaptation and validation of an argentine Spanish version of the Stanford childhood health assessment questionnaire. Arthritis and Rheumatism, 1998, 11, 382-390.	6.7	13
56	Cholestasis in juvenile dermatomyositis: Report of three cases. Arthritis and Rheumatism, 2001, 44, 1139-1142.	6.7	13
57	Interferon-Î²1aâ€“induced juvenile chronic arthritis in a genetically predisposed young patient with multiple sclerosis: Comment on the case report by Levesque et al. Arthritis and Rheumatism, 2000, 43, 1190.	6.7	10
58	Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatric Rheumatology, 2014, 12, .	0.9	6
59	Estudio multicÃ©ntrico de prevalencia de anticuerpos antirribosomal P en lupus eritematoso sistÃ©mico de comienzo juvenil comparado con lupus eritematoso sistÃ©mico del adulto. ReumatologÃa ClÃnica, 2015, 11, 73-77.	0.2	6
60	Hypertrophic osteoarthropathy in two children with cholestatic hepatic disease. Acta Paediatrica, International Journal of Paediatrics, 2005, 94, 1152-1155.	0.7	3
61	Hypertrophic osteoarthropathy in two children with cholestatic hepatic disease. Acta Paediatrica, International Journal of Paediatrics, 2005, 94, 1152-1155.	0.7	2
62	Patients with early-onset systemic juvenile idiopathic arthritis show more inflammation and worse outcome. Pediatric Rheumatology, 2011, 9, .	0.9	2
63	Recommendations for the management of autoinflammatory diseases. Pediatric Rheumatology, 2015, 13, .	0.9	2
64	Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy. Pediatric Rheumatology, 2011, 9, .	0.9	1
65	Systemic juvenile idiopathic arthritis is associated with HLA-DRB1 in Europeans and Americans of European descent. Pediatric Rheumatology, 2012, 10, .	0.9	1
66	PReS-FINAL-2236: Continuous autoinflammatory syndromes: a single-center experience in Argentina. Pediatric Rheumatology, 2013, 11, .	0.9	1
67	SP0101â€…Pediatric Rheumatology in South America. Annals of the Rheumatic Diseases, 2013, 72, A23.5-A24.	0.5	1
68	Classification of juvenile spondyloarthropaties according to asas criteria. Pediatric Rheumatology, 2014, 12, .	0.9	1
69	Multicentric Prevalence Study of Anti-P Ribosomal Autoantibodies in Juvenile Onset Systemic Lupus Erythematosus Compared With Adult Onset Systemic Lupus Erythematosus. ReumatologÃa ClÃnica (English Edition), 2015, 11, 73-77.	0.2	1
70	The prospective juvenile systemic sclerosis inceptions cohort â€“ http://www.juvenile-scleroderma.com. Pediatric Rheumatology, 2008, 6, .	0.9	0
71	Neuromyelitis optica associated with systemic autoimmune diseases in children. Pediatric Rheumatology, 2008, 6, .	0.9	0
72	13.4 High frequency of CNS involvement in linear scleroderma of the face. Pediatric Rheumatology, 2008, 6, S27.	0.9	0

#	Article	IF	Citations
73	14.2 Causes of early death in juvenile onset systemic lupus erythematosus (JSLE). Pediatric Rheumatology, 2008, 6, .	0.9	0
74	The juvenile systemic sclerosis clinic: an interdisciplinary approach. Pediatric Rheumatology, 2012, 10, .	0.9	0
75	PReS-FINAL-2120: Juvenile scleroderma international network (JUSINET) database: a reliable instrument for clinical research in juvenile scleroderma syndromes. Pediatric Rheumatology, 2013, 11, .	0.9	0
76	Share â€“ Workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile idiopathic arthritis. Pediatric Rheumatology, 2014, 12, .	0.9	0
77	SHARE â€“ workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile localized scleroderma and juvenile systemic sclerosis. Pediatric Rheumatology, 2014, 12, .	0.9	0
78	SHARE â€“ workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile dermatomyositis. Pediatric Rheumatology, 2014, 12, P89.	0.9	0
79	The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 51-58.	1.5	0
80	260â€ƒGlobalisation of Paediatric Musculoskeletal Matters (PMM). Rheumatology, 2018, 57, .	0.9	0